

CAMZYOS[®] ▼ (mavacamten) PATIENT CARD



Patient instructions: Carry this card with you **at all times**. Tell any healthcare professional who sees you that you are taking mavacamten.

Mavacamten is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. Refer to the Patient Guide and package leaflet for more information, or contact Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com.

Safety information for patients of childbearing potential:

- Mavacamten may cause harm to an unborn baby if used during pregnancy
- Mavacamten must not be taken if you are pregnant or are of childbearing potential and are not using an effective method of contraception
- If you are able to get pregnant, you must use an effective method of contraception throughout treatment and for 6 months after your last dose
- Talk to your doctor if you are considering becoming pregnant
- If you suspect that you may be pregnant or are pregnant, you must inform your prescriber or doctor **immediately**

Safety information for all patients:

- Tell your prescriber or doctor or seek other medical attention **immediately** if you experience new or worsening symptoms of heart failure, including shortness of breath, chest pain, fatigue, a racing heart (palpitations), or leg swelling
- Tell your prescriber or doctor of any new or existing medical conditions
- Tell your prescriber, doctor or pharmacist about your treatment with mavacamten before starting any new medicines (including prescription and those available over-the-counter) or herbal supplements, since some of them can increase the amount of mavacamten in your body and make it more likely for you to get side effects (some of which may be severe). Do not stop taking or change the dose of any medicine or herbal supplement that you are already taking without talking to your doctor or pharmacist first, as other medicines can affect the way mavacamten works

Please complete this section or ask your prescriber of mavacamten to complete it.


Patient's name: _____

Name of prescriber: _____

Office phone number: _____

After-hours phone number: _____

Hospital name (if applicable): _____

 This medicinal product is subject to additional monitoring. This will allow for the quick identification of new safety information. You can help by reporting any side effects that you may experience. See www.mhra.gov.uk/yellowcard for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com.

 Bristol Myers Squibb™ © 2023 MyoKardia, Inc., a Bristol Myers Squibb company.
Date of MHRA Approval: July 2023
Local Approval No.: 3500-GB-2200050,
July 2023
3500-GL-2300006 02/23